Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors.
Hims & Hers Health (HIMS) shares experienced a sell-off following its latest earnings report, despite the company report
Hims & Hers Health (HIMS) shares experienced a sell-off following its latest earnings report, despite the company reporting its first-ever quarterly net profit and raising full-year guidance. The market's 'underwhelmed' reaction appears to be driven by valuation concerns and the 'sell the news' phenomenon after the stock's massive year-to-date rally. Investors were particularly focused on the sustainability of margins as the company pivots toward personalized medicine and expands its presence in the GLP-1 weight loss space. While revenue growth remains robust at over 40% year-over-year, the high expectations baked into the stock’s premium valuation meant that anything short of a massive beat-and-raise was viewed negatively. Competitively, HIMS is navigating an increasingly crowded telehealth landscape where customer acquisition costs are rising. The forward-looking implication for investors is whether the company can maintain its subscriber growth momentum without eroding margins through increased marketing spend. Watch for the company's ability to convert GLP-1 interest into long-term, high-margin subscriptions, which will be the primary driver of the stock's recovery or further consolidation.
Watch upcoming earnings, policy statements and sector-level price action for confirmation.
Key Takeaways
- 1Hims & Hers reported its first quarter of GAAP profitability, marking a significant fundamental milestone for the telehealth provider.
- 2Despite a revenue increase of 46% year-over-year to $278.2 million, the stock fell as the market had already priced in significant growth during its 100%+ year-to-date run-up.
- 3The company raised its 2024 revenue guidance to between $1.20 billion and $1.23 billion, reflecting confidence in its new weight-loss category and personalized treatments.
- 4Marketing expenses remain a critical focal point for analysts, as the company spent $137.1 million on marketing in the quarter to drive subscriber growth.
- 5Subscriber counts grew by 41% year-over-year, reaching 1.7 million, showing strong platform adoption despite competitive pressures from Eli Lilly and Ro.
Hims & Hers Health (HIMS) shares experienced a sell-off following its latest earnings report, despite the company reporting its first-ever quarterly net profit and raising full-year guidance. The market's 'underwhelmed' reaction appears to be driven by valuation concerns and the 'sell the news' phenomenon after the stock's massive year-to-date rally. Investors were particularly focused on the sustainability of margins as the company pivots toward personalized medicine and expands its presence in the GLP-1 weight loss space. While revenue growth remains robust at over 40% year-over-year, the high expectations baked into the stock’s premium valuation meant that anything short of a massive beat-and-raise was viewed negatively. Competitively, HIMS is navigating an increasingly crowded telehealth landscape where customer acquisition costs are rising. The forward-looking implication for investors is whether the company can maintain its subscriber growth momentum without eroding margins through increased marketing spend. Watch for the company's ability to convert GLP-1 interest into long-term, high-margin subscriptions, which will be the primary driver of the stock's recovery or further consolidation.